Adaptive Radiation Boost for Rectal Cancer (ARBOR) - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.

  • By

  • September 4, 2026

  • 3 min

Share

Clinical Scorecard: Adaptive Radiation Boost for Rectal Cancer (ARBOR)

At a Glance

CategoryDetail
ConditionRectal Cancer, Adenocarcinoma
Key MechanismsAdaptive radiation therapy targeting aggressive cancer cells while protecting healthy tissue.
Target PopulationAdults aged 18 and older with histologically confirmed rectal adenocarcinoma.
Care SettingClinical trial setting for rectal cancer treatment.

Key Highlights

  • Participants receive standard chemoradiation followed by adaptive radiation therapy.
  • MRI scans are used every two weeks to adjust treatment based on tumor response.
  • A small balloon is utilized during treatment to protect healthy areas.
  • Additional chemotherapy (FOLFOX) is administered for four months post-treatment.

Guideline-Based Recommendations

Diagnosis

  • Histologically or cytologically confirmed rectal adenocarcinoma.
  • Staging via MRI pelvis and CT chest/abdomen with contrast.

Management

  • Standard treatment includes radiation (45 Gy in 25 sessions) and capecitabine.

Monitoring & Follow-up

  • MRI scans every two weeks to assess tumor response.

Risks

  • Exclusion of patients with uncontrolled intercurrent illness or prior pelvic radiation.

Patient & Prescribing Data

Adults with T2-3, N0-1, M0 rectal cancer.

Capecitabine at 825 mg/m² before ART and FOLFOX or 5-FU after ART.

Clinical Best Practices

  • Ensure normal organ and marrow function before treatment.
  • Obtain informed consent and HIPAA consent from participants.

Related Resources & Content

Original Source(s)

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

  • by

  • September 4, 2026

Related Content

Fellowship-Trained Neuro-Oncologist Nishika Karbhari, M.D., Joins Baptist Health Herbert Wertheim Cancer Institute

Fellowship-trained neuro-oncologist Nishika Karbhari, M.D., has joined Baptist Health Herbert Wertheim Cancer Institute.

  • by

  • September 3, 2026

  • 2 min
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Therapy-induced immunoediting and the evolution of cancer immune escape